Pramlintide/insulin A21G (development name ADO09) is a combination of the
amylin analogue
pramlintide and an
insulin analog. It is being developed by Adocia for diabetes.[1][2][3]
References
^Andersen, Grit; Meiffren, Grégory; Famulla, Susanne; Heise, Tim; Ranson, Aymeric; Seroussi, Cyril; Eloy, Rosy; Gaudier, Martin; Charvet, Richard; Chan, You-Ping; Soula, Olivier; DeVries, J. Hans (April 2021). "ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes". Diabetes, Obesity and Metabolism. 23 (4): 961–970.
doi:
10.1111/dom.14302.
PMID33336850.
S2CID229317541.
^Meiffren, GréGory; Andersen, Grit; Eloy, Rosy; Seroussi, Cyril; MéGret, Claire; Famulla, Susanne; Chan, You-Ping; Gaudier, Martin; Soula, Olivier; Devries, J. Hans; Heise, Tim (1 June 2020). "112-LB: ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)". Diabetes. 69 (Supplement_1).
doi:
10.2337/db20-112-LB.
S2CID225836057.
^Andersen, Grit; Eloy, Rosy; Famulla, Susanne; Heise, Tim; Meiffren, Grégory; Seroussi, Cyril; Gaudier, Martin; Mégret, Claire; Chan, You-Ping; Soula, Olivier; Riddle, Matthew (May 2023). "A co-formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes". Diabetes, Obesity and Metabolism. 25 (5): 1241–1248.
doi:
10.1111/dom.14972.
PMID36633505.
S2CID255747311.
Pramlintide/insulin A21G (development name ADO09) is a combination of the
amylin analogue
pramlintide and an
insulin analog. It is being developed by Adocia for diabetes.[1][2][3]
References
^Andersen, Grit; Meiffren, Grégory; Famulla, Susanne; Heise, Tim; Ranson, Aymeric; Seroussi, Cyril; Eloy, Rosy; Gaudier, Martin; Charvet, Richard; Chan, You-Ping; Soula, Olivier; DeVries, J. Hans (April 2021). "ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes". Diabetes, Obesity and Metabolism. 23 (4): 961–970.
doi:
10.1111/dom.14302.
PMID33336850.
S2CID229317541.
^Meiffren, GréGory; Andersen, Grit; Eloy, Rosy; Seroussi, Cyril; MéGret, Claire; Famulla, Susanne; Chan, You-Ping; Gaudier, Martin; Soula, Olivier; Devries, J. Hans; Heise, Tim (1 June 2020). "112-LB: ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)". Diabetes. 69 (Supplement_1).
doi:
10.2337/db20-112-LB.
S2CID225836057.
^Andersen, Grit; Eloy, Rosy; Famulla, Susanne; Heise, Tim; Meiffren, Grégory; Seroussi, Cyril; Gaudier, Martin; Mégret, Claire; Chan, You-Ping; Soula, Olivier; Riddle, Matthew (May 2023). "A co-formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes". Diabetes, Obesity and Metabolism. 25 (5): 1241–1248.
doi:
10.1111/dom.14972.
PMID36633505.
S2CID255747311.